Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026.

PRNewsWire • 10 hours ago

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.

PRNewsWire • 8 hours ago

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 6 hours ago

Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.

24/7 Wall Street • Oct 28, 2026

Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know

Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.

Zacks Investment Research • Oct 26, 2026

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Oct 21, 2026

Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors

Novavax (NVAX) concluded the recent trading session at $10.82, signifying a -3.91% move from its prior day's close.

Zacks Investment Research • Oct 19, 2026

Novavax shareholder Shah Capital to step back from activist role

Shah Capital, one of Novavax's top shareholders, said on Friday ​it no longer seeks to influence ‌control of the vaccine maker after restructuring into a family office.

Reuters • Oct 16, 2026

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers.

24/7 Wall Street • Oct 16, 2026

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.

Barrons • Oct 16, 2026